Drug intelligence / Profile preview

SKB501

Development stage: Unknown
Lead developer: Kelun-Biotech
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SKB501 is an antibody-drug conjugate (ADC) developed by Sichuan Kelun Botai Biomedicine. It is designed for the treatment of advanced malignant solid neoplasms, including advanced solid tumors. The drug utilizes the company's proprietary OptiDC platform, which aims to optimize ADC design for improved efficacy and safety. As of late 2024, SKB501 has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA), allowing it to enter clinical trials in China. Preclinical studies have shown promising results, but no detailed mechanism of action or specific molecular target has been publicly disclosed[1][5][6].

Beyond the preview

Go deeper on SKB501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKB501.

Explore the full profile